Natus Medical (NASDAQ:BABY) updated its FY 2019 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of $1.19-1.32 for the period, compared to the Thomson Reuters consensus estimate of $1.27. The company issued revenue guidance of $492-500 million, compared to the consensus revenue estimate of $495.95 million.Natus Medical also updated its FY19 guidance to $1.19-1.32 EPS.

A number of brokerages have issued reports on BABY. Zacks Investment Research downgraded Hancock Jaffe Laboratories from a buy rating to a hold rating in a report on Wednesday, June 26th. ValuEngine downgraded Zosano Pharma from a buy rating to a hold rating in a report on Wednesday, May 1st. BidaskClub downgraded YY from a sell rating to a strong sell rating in a report on Tuesday, July 23rd. Finally, TheStreet downgraded Trinity Industries from a b rating to a c rating in a report on Thursday, April 25th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the company’s stock. Natus Medical presently has a consensus rating of Hold and an average price target of $36.00.

Shares of Natus Medical stock traded up $0.66 on Friday, reaching $27.41. The company’s stock had a trading volume of 393,098 shares, compared to its average volume of 165,325. The firm has a market capitalization of $909.66 million, a P/E ratio of 19.30 and a beta of 0.57. Natus Medical has a 52-week low of $23.53 and a 52-week high of $37.90. The business has a 50-day simple moving average of $25.40. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.70 and a quick ratio of 1.18.

Natus Medical (NASDAQ:BABY) last posted its quarterly earnings data on Thursday, July 25th. The medical equipment provider reported $0.34 EPS for the quarter, beating the Zacks’ consensus estimate of $0.30 by $0.04. The business had revenue of $125.50 million during the quarter, compared to analysts’ expectations of $122.85 million. Natus Medical had a positive return on equity of 10.79% and a negative net margin of 7.38%. The business’s revenue was down 4.0% compared to the same quarter last year. During the same period in the previous year, the business earned $0.35 earnings per share. Research analysts expect that Natus Medical will post 1.27 earnings per share for the current year.

In related news, VP Austin Francis Noll III sold 14,250 shares of the business’s stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $26.43, for a total transaction of $376,627.50. Following the completion of the sale, the vice president now directly owns 99,443 shares in the company, valued at $2,628,278.49. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ken Ludlum sold 4,250 shares of the business’s stock in a transaction that occurred on Tuesday, June 11th. The stock was sold at an average price of $24.41, for a total value of $103,742.50. Following the sale, the director now owns 46,192 shares of the company’s stock, valued at $1,127,546.72. The disclosure for this sale can be found here. Insiders sold 48,515 shares of company stock valued at $1,264,239 over the last 90 days. Company insiders own 1.65% of the company’s stock.

About Natus Medical

Natus Medical Incorporated provides neurology, newborn care, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction and neurosurgical treatments, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.

Read More: Why are gap-down stocks important?

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.